Repligen Corporation (RGEN)

Exchange
NASDAQ
Symbol
RGEN
Sector
Life Sciences
Industry
Biological Products, (no Disgnostic Substances)
Description
Repligen Corporation develops and markets bioprocessing systems and technologies for use in the biologic drug manufacturing process in North America, Europe, Asia Pacific, and internationally. The company is headquartered in Waltham, Massachusetts.
Country
USA

Stock price

At close: December 20, 2024

  • Open
    145.70
  • High
    150.56
  • Low
    143.96
  • Close
    144.46
  • Volume
    1,581,540

Financial ratios

Dec 31, 2023

Activity ratios
Inventory turnover
2.93
Receivables turnover
5.03
Payables turnover
30.33
Working capital turnover
0.66
Days of inventory on hand (DOH)
124.44
Days of sales outstanding (DSO)
72.61
Number of days of payables
12.03
Fixed asset turnover
3.01
Total asset turnover
0.22
 Liquidity ratios
Current ratio
7.02
Quick ratio
5.54
Cash ratio
4.75
Cash conversion cycle
185.02
 Solvency ratios
Debt-to-assets ratio
0.18
Debt-to-capital ratio
0.21
Debt-to-equity ratio
0.26
Financial leverage ratio
1.43
Interest coverage
33.89
 Profitability ratios
Gross profit margin
4.92%
Operating profit margin
8.74%
Pretax margin
10.28%
Net profit margin
6.66%
Operating return on assets (Operating ROA)
1.93%
Return on assets (ROA)
1.47%
Return on total capital
2.66%
Return on equity (ROE)
2.11%